Following the success of 3 clinical trials, the US Food and Drug Administration granted approval to a once-monthly, self-injectable preventive treatment for adults with migraine.
The US Food and Drug Administration has granted approval to the first non-opioid treatment option for the management of withdrawal symptoms in adults who abruptly discontinue opioids.
The US Food and Drug Administration has expanded the indication of an approved MS drug, making it the first drug approved for use in some pediatric patients with relapsing multiple sclerosis.
The US Food and Drug Administration has approved a supplemental new drug application for the use of a previously approved drug for the treatment of hyperkalemia which may allow for more flexibility and ease...
The US Food and Drug Administration has approved a supplemental new drug application for the use of a combination therapy to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and...
The US Food and Drug Administration has approved the first drug to slow the decline of kidney function in adults with a high risk of rapidly progressing autosomal dominant polycystic kidney disease.
Based on evidence from several clinical trials, an FDA advisory committee has voted unanimously to recommend the approval of a cannabis-based oral solution for the treatment of 2 rare forms of epilepsy.
...
After reviewing data from 2 randomized placebo-controlled Phase 3 trials and an open-label extension, the FDA has approved a new option for the treatment of adults with chronic immune thrombocytopenia.
...
